[1] Pavri SN, Clune J, Ariyan S, et al.  Malignant melanoma: beyond the basics[J]. Plast Reconstr Surg, 2016, 138(2): 330e-340e.   doi: 10.1097/PRS.0000000000002367
[2] Qiu DM, Marugame T.  Comparison of time trends in skin cancer incidence (1973-97) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vol. Ⅳ−Ⅷ[J]. Jpn J Clin Oncol, 2008, 38(3): 234-236.   doi: 10.1093/jjco/hyn012
[3] Tas F, Erturk K.  Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors[J]. Melanoma Res, 2017, 27(2): 134-139.   doi: 10.1097/CMR.0000000000000332
[4] Gershenwald JE, Scolyer RA, Hess KR, et al.  Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual[J]. CA Cancer J Clin, 2017, 67(6): 472-492.   doi: 10.3322/caac.21409
[5] Rohren EM.  PET/computed tomography and patient outcomes in melanoma[J]. PET Clin, 2015, 10(2): 243-254.   doi: 10.1016/j.cpet.2014.12.006
[6]

Youland RS, Packard AT, Blanchard MJ, et al. 18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma[J/OL]. Adv Radiat Oncol, 2017, 2(2): 204−210[2019-09-09]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514257. DOI: 10.1016/j.adro.2017.02.003.
[7] Hasebe M, Yoshikawa K, Nishii R, et al.  Usefulness of 11C-methionine-PET for predicting the efficacy of carbon ion radiation therapy for head and neck mucosal malignant melanoma[J]. Int J Oral Maxillofac Surg, 2017, 46(10): 1220-1228.   doi: 10.1016/j.ijom.2017.04.019
[8]

Malik D, Sood A, Mittal BR, et al. Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in restaging and prognos is of recurrent melanoma after curative surgery[J]. World J Nucl Med, 2019, 18(2): 176−182. DOI: 10.4103/wjnm.WJNM_37_18.
[9] Jiang C, Zhang X, Jiang M, et al.  Assessment of the prognostic capacity of pretreatment, interim, and post-therapy 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type[J]. Ann Nucl Med, 2015, 29(5): 442-451.   doi: 10.1007/s12149-015-0964-8
[10] Biehl KJ, Kong FM, Dehdashti F, et al.  18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?[J]. J Nucl Med, 2006, 47(11): 1808-1812.
[11] Larson SM, Erdi Y, Akhurst T, et al.  Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis[J]. Clin Positron Imaging, 1999, 2(3): 159-171.   doi: 10.1016/s1095-0397(99)00016-3
[12] Seban RD, Nemer JS, Marabelle A, et al.  Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics[J]. Eur J Nucl Med Mol Imaging, 2019, 46(11): 2298-2310.   doi: 10.1007/s00259-019-04411-7
[13] Ravichandran S, Nath N, Jones DC, et al.  The utility of initial staging PET-CT as a baseline scan for surveillance imaging in stage Ⅱ and Ⅲ melanoma[J]. Surg Oncol, 2020, 35: 533-539.   doi: 10.1016/j.suronc.2020.10.018
[14] Gellén E, Sántha O, Janka E, et al.  Diagnostic accuracy of 18F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma[J]. J Eur Acad Dermatol Venereol, 2015, 29(10): 1938-1944.   doi: 10.1111/jdv.13084
[15] Kang S, Ahn BC, Hong CM, et al.  Can 18F-FDG PET/CT predict recurrence in patients with cutaneous malignant melanoma?[J]. Nuklearmedizin, 2011, 50(3): 116-121.   doi: 10.3413/Nukmed-0356-10-09
[16] Son SH, Kang SM, Jeong SY, et al.  Prognostic value of volumetric parameters measured by pretreatment 18F FDG PET/CT in patients with cutaneous malignant melanoma[J]. Clin Nucl Med, 2016, 41(6): e266-e273.   doi: 10.1097/RLU.0000000000001205
[17] Agarwala SS, Keilholz U, Gilles E, et al.  LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)[J]. Eur J Cancer, 2009, 45(10): 1807-1814.   doi: 10.1016/j.ejca.2009.04.016
[18] Schmitt RJ, Kreidler SM, Glueck DH, et al.  Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma[J]. Nucl Med Commun, 2016, 37(2): 122-128.   doi: 10.1097/MNM.0000000000000406